Capnia (SLNO) Earns Coverage Optimism Score of 0.39
News coverage about Capnia (NASDAQ:SLNO) has trended positive this week, Accern Sentiment Analysis reports. The research group identifies negative and positive press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Capnia earned a media sentiment score of 0.39 on Accern’s scale. Accern also gave news headlines about the company an impact score of 48.8555019607504 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Separately, Maxim Group set a $5.00 target price on shares of Capnia and gave the company a “buy” rating in a research note on Thursday, May 4th.
Capnia (NASDAQ SLNO) opened at 0.4885 on Friday. The firm’s market cap is $23.41 million. Capnia has a 52 week low of $0.30 and a 52 week high of $1.32. The company has a 50-day moving average of $0.49 and a 200 day moving average of $0.62.
Capnia (NASDAQ:SLNO) last announced its quarterly earnings data on Friday, August 11th. The company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.02. Capnia had a negative return on equity of 69.67% and a negative net margin of 1,389.76%. On average, equities analysts predict that Capnia will post ($0.27) earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: This news story was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States and international trademark and copyright laws. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2017/08/27/capnia-slno-earns-coverage-optimism-score-of-0-39.html.
Capnia Company Profile
Soleno Therapeutics, Inc, formerly Capnia, Inc, is a healthcare company that develops and commercializes neonatology devices and diagnostics. The Company also has a therapeutics platform based on its proprietary technology for precision metering of gas flow. The Company offers products, such as CoSense end-tidal carbon monoxide (ETCO) Monitor, NeoPIP Infant Resuscitator and Accessories, and Serenz Nasal Relief.
Receive News & Stock Ratings for Capnia Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capnia Inc. and related stocks with our FREE daily email newsletter.